 |
|
|
| |
Activity of Telaprevir Alone or in Combination with Peginterferon Alfa-2a and Ribavirin in Treatment-naïve, Genotype 2 and 3, Hepatitis C Patients: Final Results of Study C209
|
| |
| |
Reported by Jules Levin at
EASL Apr 14-18 2010 Vienna Austria
Graham R Foster, Christophe Hezode, Jean-Pierre Bronowicki, Giampiero Carosi, Ola Weiland, Lieselotte Verlinden, Rolf van Heeswijk, Ben Van Baelen, Gaston Picchio, Maria Beumont-Mauviel
G = HCV genotype; Peg-IFN = pegylated interferon; RBV = ribavirin; SVR = sustained virological response
1McHutchison JG, et al. N Engl J Med 2009;360:1827-38; 2Hezode C, et al. N Engl J Med 2009;360:1839-50;
3Hadziyannis, et al. Ann Inter Med 2004;140:; 4Lin C, et al. 42nd EASL 2007, Abs 12
TVR 750mg q8h; Peg-IFN alfa-2a 180µg/week; RBV 800mg/day
EOT = end of treatment; PBO = placebo
*Two subjects withdrew consent, one was enrolled in error and did not meet inclusion criteria
*Genotype and subtype were determined based on the NS5B region
All patients received 24 weeks of Peg-IFN and RBV therapy
* Follow-up data
vBT = viral breakthrough
*>1 log increase in HCV RNA from nadir or >100 IU/mL if prior <25 IU/mL
**Including 4 subjects with an unconfirmed vBT during the TVR treatment phase (similar to Week 2 analysis
*A detailed genotypic and phenotypic analysis is presented in poster #1831
**Mutations in the NS3 region associated with reduced susceptibility to Telaprevir : V36A/M, T54A, R155I/K/M/T, A156S/T/V
*A detailed genotypic and phenotypic analysis is presented in poster #1831
**Mutations in the NS3 region associated with reduced susceptibility to Telaprevir : V36A/M, T54A, R155I/K/M/T, A156S/T/V
*Genotype and subtype were determined based on the NS5B region
All patients received 24 weeks of Peg-IFN and RBV therapy
*Follow-up data
*A detailed genotypic and phenotypic analysis is presented in poster #1831
**Mutations in the NS3 region associated with reduced susceptibility to Telaprevir : V36A/M, T54A, R155I/K/M/T, A156S/T/V
AEs occurring in >20% in any group are shown; **Grade 3 rash for which subject discontinued TVR treatment
|
| |
|
|
|
|
|
